Adding lomustine to the standard combination of idarubicin and cytarabine for the treatment of old patients with acute myeloid leukemia improves complete response rates and overall survival. These findings emphasize the importance of dose intensity and raise the question of a unique role for nitrosoureas in the treatment of this disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pigneux, A. et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J. Clin. Oncol. 28, 3028–3034 (2010).
Pigneux, A. et al. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica 92, 1327–1334 (2007).
Schiller, G. J. et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J. Clin. Oncol. 28, 815–821 (2010).
Kahn, S. B. et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol. 2, 865–870 (1984).
Löwenberg, B. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361, 1235–1248 (2009).
Appelbaum, F. R. et al. Age and acute myeloid leukemia. Blood 107, 3481–3485 (2006).
Sorror, M. L. et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25, 4246–4254 (2007).
Giles, F. J. et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br. J. Haematol. 136, 624–627 (2007).
Rizzieri, D. et al. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin. Lymphoma Myeloma Leuk. 10, 211–216 (2010).
Gerson, S. L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4, 296–307 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Appelbaum, F. Lo and behold, a role for lomustine in acute myeloid leukemia?. Nat Rev Clin Oncol 7, 619–621 (2010). https://doi.org/10.1038/nrclinonc.2010.169
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.169
